Two hundred and twenty-two myeloma patients autografted after 200 mg/m 2 melphalan were studied to examine the relationship between response to induction chemotherapy and outcome. Induction comprised cyclophosphamide, vincristine, doxorubicin and methylprednisolone (C-VAMP) every 3 weeks for one cycle beyond maximum response. 81% responded to C-VAMP (chemosensitive) with 40 complete (CR) and 139 partial (PR) remissions, and 43 did not respond (NR; Ͻ50% reduction in paraprotein; primary refractory). Overall, 130 patients (59%) attained or remained in CR posttransplant; including 40% of NR, 53% of PR, and 97% of CR after C-VAMP (P Ͻ 0.0001). Amongst these 130 patients, the 5-year OS was independent of response to C-VAMP (NR 79%, PR 74%, CR 60%; P = 0.69). Similarly, among the 69 patients in PR post-transplant, the 5-year OS was independent of response to C-VAMP. In Cox analysis, lack of response to C-VAMP did not affect outcome significantly. These data show that lack of response to induction therapy does not automatically predict poor long-term outcome in myeloma, since a substantial proportion of these patients attain CR after autograft and enjoy extended survival. Myeloma patients should not be disqualified from an autograft based upon lack of response to induction chemotherapy.
chemotherapy. 5 Amongst hematologic malignancies treated with autotransplantation, 6 myeloma is unique in that autografts are performed in a substantial proportion of patients before they have attained complete remission (CR) -and most patients attaining CR do so as a result of the transplant. 4, 7 Patients with primary refractory myeloma -disease that does not respond adequately to induction chemotherapyhave a poor prognosis with short survival. Dose-intensive therapy has been shown to improve the outcome of these patients in comparison with those treated conventionally. 8, 9 There are no data comparing the outcome of patients with disease responding to induction chemotherapy (chemosensitive) and that of those with disease not responding adequately to induction chemotherapy (primary refractory) after autotransplantation. There is a prevalent perception that the outcome of patients with primary refractory disease is considerably worse than that of those with chemosensitive disease despite an autograft. This often results in lack of insurance approval for autotransplantation in myeloma patients with primary refractory disease. Medicare, the health care coverage program for Americans aged 65 and older covers autografting only in myeloma patients who are responsive to chemotherapy -which, by definition, excludes patients with primary refractory disease. 10 As it has been our practice to autograft all patients irrespective of response to induction chemotherapy, the outcome of a group of 222 uniformly treated patients was studied to assess the impact of chemosensitivity on relapse, event-free survival (EFS) and overall survival (OS) after autotransplantation.
Patients and methods
Two hundred and twenty-two consecutive patients treated at the Royal Marsden Hospital between 1993 and 2001 who fulfilled the following criteria were studied: no prior transplant or non-myeloablative high-dose melphalan, untreated or minimally previously treated (one to two cycles of previous therapy) disease, induction chemotherapy with C-VAMP (Table 1) , G-CSF-mobilized peripheral blood stem cell collection, and autotransplant following 200 mg/m 2 melphalan. This number excludes myeloma patients who were autografted, but did not fulfill these criteria, and those who received C-VAMP but did not proceed to an autograft. Cycles are repeated every 3 weeks, and continued for one cycle beyond maximum response.
During the period in question, the proportion of patients started on induction therapy who did not proceed to an autograft was approximately 23%. Epidemiologic and disease-specific information was gathered on each patient prospectively and in real time in a comprehensive database. 11 Patients provided informed consent for the therapy, and experimental protocols were approved by the institutional review board.
Response criteria
Paraprotein and immunoglobulin levels were estimated regularly to assess response, and bone marrow examination was performed as needed. Patients with clearly progressive bone disease before the transplant were classified as nonresponders. The response criteria have been described before, 12 and were as follows in brief: CR: Disappearance of monoclonal protein from serum and urine by immunoelectropheresis with a normal bone marrow (Ͻ5% plasma cells); sustained for 3 months. Immunofixation-negativity was not required to define CR. Partial response (PR): 50% reduction in the quantity of monoclonal protein (50% reduction in marrow infiltration in patients with nonsecretory disease); sustained for 1 month. Relapse: Reappearance of paraprotein or Ͼ5% plasma cells in the marrow for patients in CR, 25% increase in paraprotein on 2 occasions a month apart for patients in PR, or progressive bone disease. Patients experiencing Ͻ50% reduction in paraprotein (or marrow plasmacytosis in case of non-secretory disease) were considered to have primary refractory disease.
Treatment plan
C-VAMP chemotherapy (Table 1 ) was administered every 3 weeks for one cycle beyond maximum response. After this, an additional cycle was administered. The median number of cycles of C-VAMP received by the whole group as well as the subgroups with chemosensitive and primary refractory disease was five. Primary refractory patients received a trial of at least two cycles of chemotherapy. Thus, patients were not considered to have failed therapy after just one cycle of C-VAMP.
Stem cells were mobilized with 12-16 g/kg G-CSF (rounded off to the nearest 300 or 480 g vial size) once patients achieved a stable plateau. This was done irrespective of disease status and the extent of marrow infiltration After adequate marrow recovery (usually leukocytes Ͼ3 ϫ 10 9 /l and platelets Ͼ50 ϫ 10 9 /l), subcutaneous interferon-␣2b was started at the dose of 3 MU/m 2 three times a week and was continued until disease progression.
13,14

Statistical analysis
The 2 test was used to compare categoric variables and the Wilcoxon rank-sum test to compare continuous variables. Probabilities of EFS and OS were estimated using the method of Kaplan and Meier, and compared using the logrank test. Cumulative incidence of TRM and relapse was estimated using each type of event as a competing risk for the other. The significance of differences in TRM and relapse was calculated using the likelihood-ratio statistic for proportional-hazards regression models.
Two patients who were allografted after the autograft were censored at the time of the allogeneic transplant for TRM and OS. One was in PR after the autograft and was censored on the day of allograft for relapse and EFS. One did not respond to the autograft at all and was considered a failure (an event) on the day of autograft for computing relapse and EFS. Five patients dying 4-56 months after autograft of causes unrelated to myeloma or the transplant (pulmonary aspergillosis, toxicity of maintenance chemotherapy, glioblastoma, secondary acute myeloid leukemia and cardiac arrest) were considered to be failures for EFS and OS, and were censored for computing relapse and TRM at the time of death.
Finally, Cox proportional-hazards regression models were used to determine which of the following factors influenced TRM, relapse, EFS and OS independently: gender, age (Ͻ65 vs у65 years), isotype (IgA vs others), Durie-Salmon stage (III vs others), performance status at transplant (0/1 vs 2), prior therapy (yes vs no), response to C-VAMP (chemosensitive vs primary refractory), albumin (Ͻ3.5 vs у3.5 g/dl), ␤2-microglobulin (р2.5 vs Ͼ2.5 mg/l), calcium (р2.4 vs Ͼ2.4 mmol/l), and creatinine (р150 vs Ͼ150 mol/l).
Multivariable analysis was also performed with attainment (or continuation) of CR post-transplant as an additional variable among patients alive at 12 weeks (to exclude the 18 treatment-related deaths occurring within 12 weeks). This landmark analysis was used to investigate relapse, OS and EFS. Once significant prognostic factors had been identified, exploratory analyses were carried out to try and identify a subgroup of patients with a very poor prognosis. Figure 1 shows the flow of patients through the treatment program and Table 2 shows patient characteristics. Of the 43 patients classified as NR to C-VAMP in accordance with the definition of response, 13 had disease that actually con- tinued to progress through C-VAMP chemotherapy, whereas 30 had disease that was stable or had responded inadequately (Ͻ50%). The outcome of these two subgroups was comparable (data not shown), and therefore the NR group was not split into subgroups for any of the analyses.
Results
Transplant-related mortality
Eighteen patients died of transplant-related complications after the autograft; all within 12 weeks. These were the only deaths that occurred in the first 12 weeks post transplant. TRM was significantly higher in the primary refrac- 
Outcome by response to induction chemotherapy
As Figures 2 and 3 show, the outcome of patients with chemosensitive and primary refractory disease was not significantly different. Among the 130 patients attaining or continuing in CR after the transplant who were alive and well 12 weeks post-transplant, EFS was not affected by whether the response to C-VAMP was CR, PR or NR Bone Marrow Transplantation Figure 3 The effect of response to induction chemotherapy on eventfree survival after high-dose melphalan and autograft in all patients (P = 0.19). The early difference is mainly due to higher TRM in the primary refractory group.
( Figure 4 ). Amongst the 69 patients alive and well 12 weeks post-transplant and attaining or continuing in PR after the transplant, the EFS was not affected by whether the response to C-VAMP was PR or NR ( Figure 5 ).
Multivariable analysis
As Table 3 shows, compromised renal function and low serum albumin at the time of the autograft were associated with higher TRM, and a high ␤2-microglobulin with lower EFS and OS. No factor was independently associated with a higher risk of disease progression. When the final response status post-transplant was included in the model after adjusting for survival at 12 weeks, attainment of CR emerged as a significant predictor of relapse and EFS, and low albumin was found to be associated with lower EFS and OS. 
High-risk group of patients
A small subgroup of patients (n = 17) identified by primary refractory disease, ␤2-microglobulin Ͼ2.5 mg/l and albumin Ͻ3.5 g/dl at the time of the autograft had an exceedingly poor outcome with significantly higher TRM (7 of 17 vs 11 of 205; P Ͻ 0.0001), more rapid relapse (37% vs 21% at 1.5 years; P = 0.004), and poorer EFS (median 0.8 vs 3.3 years; Figure 6 ). Interestingly, the 26 patients with primary refractory disease whose ␤2-microglobulin and albumin levels were favorable (р2.5 mg/l and (у3.5 g/dl respectively) fared as well as those with chemosensitive disease ( Figure 7 ) and had comparable TRM (1 of 26 vs 10 of 179; P = 0.58).
Discussion
This report is the first to show that the outcome of a significant proportion of patients with primary refractory disease is comparable to that of patients with chemosensitive disease undergoing high-dose chemotherapy.
There are limited data in the literature of high-dose therapy in patients with primary refractory myeloma. 8, 9, 15, 16 They show that patients with primary refractory disease receiving high-dose therapy fare better than those not undergoing high-dose therapy, 8, 9 and that the outcome of patients with refractory relapse treated with high-dose therapy is significantly worse than those with primary refractory disease treated similarly. 15, 16 These data have significant practical implications. They show that the practice of withholding high-dose therapy from patients with primary refractory myeloma, including Medicare's policy of restricting coverage of high-dose therapy to myeloma patients with chemosensitive disease, 10 may need reconsideration.
It is not known if this conclusion would be applicable to patients receiving induction chemotherapy other than C-VAMP. We believe it would be because most autografted patients are induced with VAD which is similar to C-VAMP. Also, C-VAMP, the way it was delivered in this High-risk Figure 6 Event-free survival of the 'high-risk' group compared with the rest of the patients (P Ͻ 0.001). study, represents relatively intensive induction therapy for myeloma. If patients refractory to C-VAMP could respond to an autograft, it would be reasonable to expect that those with disease refractory to less intensive induction therapy, such as VAD would also respond to an autograft. Data on chromosome 13 abnormalities were not available in these patients. However, since the major thrust of the study was correlating response to induction chemotherapy with outcome, we do not believe this affects the conclusions in any way.
If alternative therapy (ie non-high dose) rather than an autograft were to be considered in a subgroup of patients, the high-risk group would appear to be the one. While our data cannot rule out benefit of autotransplantation compared to no autograft in this small proportion of patients (under 10% of the entire group), their outcome with highdose melphalan and autotransplantation is so poor that a change in strategy is clearly warranted to improve outcome. This could be the administration of novel salvage therapy such as thalidomide 17, 18 or PS-341 19 after failure of induction therapy. Responses to thalidomide are associated with improvements in ancillary parameters: decline in ␤2-microglobulin, creatinine, and C-reactive protein, and increase in hemoglobin and albumin. 20 It is possible that successful salvage treatment may restore the outcome of these patients to a level comparable with the remaining patients with subsequent autotransplantation. These patients could then perhaps be candidates for thalidomide or PS-341 maintenance therapy after autograft. 18, 20 The response rate of our primary refractory group to high-dose melphalan and autotransplantation is higher than that reported by the MD Anderson group. 8, 9 There could be several reasons for this. One is that we proceeded directly to autotransplantation without trying salvage induction regimens or prolonging induction therapy beyond the minimum required to demonstrate lack of response in any given patient. The second reason may be our use of 200 mg/m 2 melphalan as the conditioning regimen -which has been shown to be the optimal regimen for treatment intensification in patients with myeloma. 4, [21] [22] [23] The MD Anderson group has, for the patients they have reported, usually employed regimens other than 200 mg/m 2 melphalan. 8, 9 We have also used immunoelectrophoresis rather than immunofixation to define CR -which may overestimate the proportion of patients in CR. It should also be noted that the main focus of this study was the effect of lack of response to induction rather than examination of the extent of response in responding patients. We have shown in the past that attainment of CR with induction chemotherapy is a good prognostic indicator. 24 This study complements our prior results by showing that lack of response is not necessarily a poor prognostic indicator.
If lack of response to induction chemotherapy does not affect the decision to transplant a patient with myeloma, is there any point in giving induction chemotherapy? The answer to this question is unknown. We have shown that the speed of clearance of paraprotein -and therefore attainment of remission -is faster after high-dose melphalan than after C-VAMP-type induction therapy. 25 We have therefore started a study of 200 mg/m 2 melphalan as primary therapy of myeloma using peripheral blood stem cells harvested at the time of presentation with no prior cytoreduction. 26 C-VAMP has not been eliminated, but has been shifted to a later phase of therapy -and is administered as post-transplant consolidation based upon our prior observations of post-transplant intensive chemotherapy. 27 The idea is to see if the faster attainment of CR increases the proportion of patients remaining in remission long-term ('operational cure'). 28 In conclusion, patients with primary refractory myeloma should receive high-dose melphalan and undergo autotransplantation because a substantial proportion of them respond well and obtain survival benefit. A small subgroup of these patients -those with adverse ␤2-microglobulin and albumin levels -may be candidates for novel therapies other than or prior to autotransplantation.
